© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Aytu BioPharma, Inc. (AYTU) stock surged +0.39%, trading at $2.60 on NASDAQ, up from the previous close of $2.59. The stock opened at $2.67, fluctuating between $2.59 and $2.67 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 18, 2026 | 2.67 | 2.67 | 2.59 | 2.60 | 84.38K |
| Mar 17, 2026 | 2.65 | 2.69 | 2.58 | 2.59 | 39.75K |
| Mar 16, 2026 | 2.62 | 2.70 | 2.61 | 2.64 | 32K |
| Mar 13, 2026 | 2.69 | 2.69 | 2.54 | 2.54 | 24.5K |
| Mar 12, 2026 | 2.63 | 2.70 | 2.56 | 2.64 | 38.13K |
| Mar 11, 2026 | 2.49 | 2.64 | 2.49 | 2.60 | 52.17K |
| Mar 10, 2026 | 2.64 | 2.66 | 2.58 | 2.60 | 17.11K |
| Mar 09, 2026 | 2.52 | 2.68 | 2.37 | 2.61 | 61.8K |
| Mar 06, 2026 | 2.48 | 2.57 | 2.46 | 2.52 | 44.95K |
| Mar 03, 2026 | 2.60 | 2.69 | 2.53 | 2.64 | 47.77K |
| Mar 02, 2026 | 2.55 | 2.68 | 2.44 | 2.64 | 88.8K |
| Feb 27, 2026 | 2.42 | 2.58 | 2.42 | 2.57 | 119.97K |
| Feb 26, 2026 | 2.33 | 2.51 | 2.33 | 2.46 | 49.07K |
| Feb 25, 2026 | 2.25 | 2.33 | 2.25 | 2.31 | 17.96K |
| Feb 24, 2026 | 2.16 | 2.32 | 2.16 | 2.27 | 31.67K |
| Feb 23, 2026 | 2.26 | 2.29 | 2.23 | 2.27 | 21.83K |
| Feb 20, 2026 | 2.30 | 2.40 | 2.28 | 2.30 | 14.44K |
| Feb 19, 2026 | 2.27 | 2.40 | 2.27 | 2.31 | 21.85K |
| Feb 18, 2026 | 2.18 | 2.35 | 2.18 | 2.31 | 71.11K |
| Feb 17, 2026 | 2.15 | 2.19 | 2.15 | 2.17 | 24.59K |
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
| Employees | 102 |
| Beta | 0.34 |
| Sales or Revenue | $66.38M |
| 5Y Sales Change% | -0.912% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |